Home › Funds › SG Americas Securities, LLC › ABT

SG Americas Securities, LLC position in ABT

ABBOTT LABORATORIES · Health Care

SG Americas Securities, LLC reported holding 7,197,405 shares of ABT (ABBOTT LABORATORIES) in its Q2 2026 13F filing — a position valued at US$618.0M, representing 0.35% of its reported portfolio and ranking #43 among its reported holdings. SG Americas Securities, LLC has disclosed ABT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)7.20M sh
Reported value held$618.00M
Portfolio Weight0.35%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How SG Americas Securities, LLC's ABT position evolved

SG Americas Securities, LLC first disclosed a stake in ABT in Q3 2023 at 48,207 shares (US$4.7M). The position peaked in Q2 2026 at 7,197,405 shares, worth US$618.0M. Across 12 filings, SG Americas Securities, LLC increased the stake 8 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 7,197,405 shares valued at US$618.0M — an increase of 5,133,248 shares quarter over quarter.. Notable position changes include a 367% increase in Q4 2023 (shares rose 4% over the following quarter), a 257% increase in Q1 2025 (shares rose 3% over the following quarter), a 249% increase in Q2 2026 (shares rose 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 48.21K $4.67M New
Q4 2023 225.04K $24.77M Add
Q1 2024 508.60K $57.81M Add
Q2 2024 446.95K $46.44M Reduce
Q3 2024 337.95K $38.53M Reduce
Q4 2024 33.70K $3.81M Reduce
Q1 2025 120.17K $15.94M Add
Q2 2025 199.88K $27.18M Add
Q3 2025 590.27K $79.06M Add
Q4 2025 962.79K $120.63M Add
Q1 2026 2.06M $211.93M Add
Q2 2026 7.20M $618.00M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has SG Americas Securities, LLC held ABT?

SG Americas Securities, LLC has disclosed ABT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is SG Americas Securities, LLC's current position in ABT?

As of Q2 2026, SG Americas Securities, LLC holds 7.20M shares of ABT (ABBOTT LABORATORIES), valued at $618.00M, representing 0.35% of its reported portfolio and ranking #43.

Has SG Americas Securities, LLC been buying or selling ABT?

In the latest 13F filing (Q2 2026), SG Americas Securities, LLC increased its position in ABT. The position peaked in Q2 2026 at 7.20M shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.